阿尔茨海默病（AD）是一种典型多因素复杂疾病，针对单一靶点研发的临床一线药物疗效不尽人意。多靶协同的中医策略对AD防治具有指导性意义。天泰1号是基于AD“肝虚髓亏”中医病理新假说和长期临床经验研制的医院制剂。研究显示其通过促进核心病理产物降解、拮抗内质网应激、抗氧化、抗凋亡、增强胆碱能活性和突触可塑性等多种途径干预AD。天泰1号临床效果显著，但其药效物质基础尚未清楚。鉴此，本项目采用网络药理学筛选天泰1号抗AD活性成分群、靶点群，通过分子对接、网络拓扑分析明确“活性成分-靶点-疾病”的网络关系；以体内直接作用物质为切入点，以脑脊液谱效学新方法，研究脑脊液药物成分“量”的动态变化与细胞模型“效”的关系。整合网络药理学和脑脊液谱效学，明确天泰1号抗AD的物质基础；通过网络拓扑分析，解析天泰1号多组分协同抗AD的整合机制，为实现由传统中药组方向新型中药复方（组分中药）转化提供科学依据。

Alzheimer's disease (AD) is a typical complex multi-factorial disease. The effect of single-target drug was unsatisfactory. TCM treatment strategy of multi-target therapeutics has guiding significance for the treatment of AD. Tiantai No.1 is a Hospital preparation which was developed on the basis of AD "gan xu sui kui" new pathological hypotheses and long-term clinical experience. Pharmacological studies have shown that Tiantai No.1 intervenes AD pathology process by promoting its core pathological product degradation, anti- endoplasmic reticulum stress, anti-oxidation, anti-apoptosis, enhancing cholinergic activity and hippocampal synaptic plasticity, and so on. Tiantai No.1 has a significant curative effect on AD, but the material basis of its efficacy has not been clear.Therefore, network pharmacology will be used to predict active ingredients and targets of Tiantai No.1 against Alzheimer disease, molecular docking technology and network topology feature analysis will be used to clarify the network relationship of "ingredient - target - disease". Cerebrospinal fluid spectrum-efficiency study,as a new method,will be used to study the relationship between the “quantity” of chemical composition in cerebro-spinal and “effect” in cell experiment. Clearify the active ingredients of Tiantai No.1 against Alzheimer disease by integrating network pharmacology and Cerebrospinal fluid spectrum-efficiency study,and systematically elucidate the scientific compatibility among components.Screening the active ingredients for different target through the network characteristics to achieve the new forms multi-component Chinese Medicine.